Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.
Gender-related differences in the efficacy and safety of ritonavir-boosted tipranavir [tipranavir/ritonavir (TPV/r) 500/200 mg twice daily (b.i.d.)] were evaluated in a subanalysis of the Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients with Tipranavir (RESIST) trials. Data from HIV-1-infected women (203; TPV/r = 117) and men (1280; TPV/r = 629) showed no significant gender-related differences in HIV RNA response rates (at 48 weeks) and safety (at 96 weeks) despite higher mean steady-state plasma TPV trough concentrations in women. Significantly greater increases in CD4 cell count (+81.2 vs. +48.6; P = 0.0012) were observed in women at week 48.
Walmsley
Sharon L
SL
University Health Network, University of Toronto, Canada. sharon.walmsley@uhn.on.ca
Squires
Kathleen
K
Weiss
Laurence
L
Easterbrook
Philippa
P
Orani
Anna
A
Kraft
Michael
M
Scherer
Joseph
J
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D024921:Drug Resistance, Multiple, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011753:Pyrones / Q000009:adverse effects / Q000627:therapeutic use*; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use*; D012737:Sex Factors; D013449:Sulfonamides; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D004338:Drug Combinations; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D019438:Ritonavir; C107201:tipranavir